联合应用以Hif-1α和Survivin基因为靶标的siRNA对鼻咽癌CNE-2细胞增殖和周期的影响  

Combined application the siRNA target for Hif-1α and Survivin gene to human NPC CNE-2 cell and its effects on the proliferation and cycle of this cell

作　　者：任艳鑫[1] 张书萍[2] 李晓江[1] 杨洁[1] 孙瑞梅[1] 赵留芳[1] 李磊[1] 

机构地区：[1]昆明医科大学第三附属医院头颈肿瘤研究中心,昆明650118 [2]四川省人民医院城东病区耳鼻咽喉科

出　　处：《临床耳鼻咽喉头颈外科杂志》2014年第24期1975-1978,共4页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

基　　金：2012年国家自然科学基金地区项目(No:81260312);2011年云南省卫生科技内设研究机构项目资助(No:2011WS0068);云南省社会发展科技计划(应用基础研究重点项目)(No:2009CC026)

摘　　要：目的:研究联合转染以乏氧诱导因子-1α(Hif-1α)和Survivin基因为靶标的siRNA后,鼻咽癌CNE-2细胞增殖和周期的改变。方法:以Hif-1α和Survivin基因为靶标的siRNA共同转染鼻咽癌CNE-2细胞,以单靶点siRNA转染组和未处理组为对照。MTT检测转染后细胞的增殖活力;流式细胞仪检测转染后细胞的周期变化,RT-PCR与Western Blot技术检测转染后各组细胞相应靶基因mRNA及相关蛋白表达水平的变化。结果:鼻咽癌CNE-2细胞分别转染以Hif-1α和Survivin基因为靶标的siRNA后,细胞的增殖能力明显下降,相应靶基因的mRNA及蛋白的表达明显减低,细胞周期出现G0/G1期阻滞;联合转染两种siRNA后细胞的各项检测结果均明显强于对照组,与各组相比差异均有统计学意义(P<0.01)。结论:联合以Hif-1α和Survivin基因为靶标的siRNA干扰组,可以较单基因干扰组更有效干扰鼻咽癌CNE-2细胞内靶基因mRNA和蛋白的表达,抑制细胞的增殖。Objective：To study the combined transfection of the siRNA target for Hif-1α and Survivin gene to human NPC CNE-2 cell and its effects on the proliferation and cycle of this cell. Method：Combined transfection of the siRNA target for Hif-1α and Survivin gene to human NPC CNE-2 cell, these plasmids were respectively trans- fected into the same cells. Cell proliferation was detected with MTT assay. The inhibitory effects on target genes were evaluated with RT-PCR and Western Blot at the levels of mRNA and protein, respectively. Result.. MTT showed that CNE-2 cell proliferation in multi-gene plasmid group was more significantly inhibited than a single gene. The expression of mRNA and protein of two different genes were both decreased in HS group, and the in- terference effect of multiple genes was better than the single-gene（P〈0. 01）. Conclusion： HS group could restrain cell proliferation and interference the mRNA and protein expression in nasopharyngeal carcinoma CNE-2 cell, which was better than the other groups.

关 键 词：鼻咽肿瘤 RNA干扰 乏氧诱导因子-1Α 存活素 

分 类 号：R739.63[医药卫生—肿瘤]